The agreement addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states.

Under the terms of the agreement, Salus is granted exclusive rights to market and sell Pepaxti in Slovenia, Croatia, Hungary, Slovakia, the Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, and Estonia.

Salus will be responsible for local regulatory processes, market access, and commercialization in the agreed territories, while Oncopeptides retains the overall responsibility for the manufacturing and supply of the drug. Sales revenues generated within the agreed territories shall be shared between Oncopeptides and Salus, with Oncopeptides entitled to the greater portion thereof.

“We are very pleased to enter this partnership with Salus, whose strong regional presence and expertise make them the ideal partner for this market,” says Sofia Heigis, CEO of Oncopeptides. “This agreement enables us to make Pepaxti available to patients in Central and Eastern Europe faster than originally planned. We see significant strategic value in the fact that revenue streams from these markets are now projected to arrive earlier than assumed in our previous launch strategy.”